Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Medicrea. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Medicrea's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medicrea has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
No analysts cover Medicrea, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Medicrea's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Medicrea's earnings growth to the France market average as no estimate data is available.
Unable to compare Medicrea's revenue growth to the France market average as no estimate data is available.
Unable to determine if Medicrea is high growth as no earnings estimate data is available.
Unable to determine if Medicrea is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Medicrea's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Denys Sournac serves as the Owner, President and Chief Executive Officer at Orsco Laboratoire Vétérinaire, SAS. He also serves as the Chairman of Orsco Laboratoire Vétérinaire, SAS. Mr. Sournac has been a Director at Medicrea since March 29, 2002.
Denys's compensation has been consistent with company performance over the past year.
Denys's compensation appears reasonable for a company of this size and profit level.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Medicrea management team is less than 2 years, this suggests a new team.
Chief Financial Officer
Chief Information Officer
Chief Scientific Officer
Vice President of Human Ressources & Legal
Vice President of Product Development & Marketing
Chief Commercial & Business Development Officer and Director
Executive Vice President of U.S. Sales
Executive Vice President of UNiD™ ASI
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the Medicrea board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
Chief Commercial & Business Development Officer and Director
What You Must Know About Medicrea's (EPA:ALMED) Major Investors
In this analysis, my focus will be on developing a perspective on Medicrea’s (EPA:ALMED) latest ownership structure, a less discussed, but important factor. … The impact of a company's ownership structure affects both its short- and long-term performance. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.
Medicrea (EPA:ALMED) is a small-cap stock with a market capitalization of €39.20m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Medical Equipment companies,
With A -41.36% Earnings Drop, Is Medicrea's (EPA:ALMED) A Concern?
After reading Medicrea's (ENXTPA:ALMED) most recent earnings announcement (31 December 2017), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … I use data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … Though Medicrea's past data is helpful, it is only one aspect of my investment thesis.
How Does Medicrea (EPA:ALMED) Affect Your Portfolio Returns?
A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … Based on this beta value, ALMED appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … However, this is the opposite to what ALMED’s actual beta value suggests, which is lower stock volatility relative to the market.
ALMED has built up its total debt levels in the last twelve months, from €10.43M to €21.91M , which comprises of short- and long-term debt. … Moving onto cash from operations, its trivial cash flows from operations make the cash-to-debt ratio less useful to us, though these low levels of cash means that operational efficiency is worth a look. … Since total debt levels have outpaced equities, ALMED is a highly leveraged company.
Medicrea designs, manufactures, and distributes implants in France. It offers PASS range, a polyaxial spine system; PASS LP, a thoraco-lumbar fixation system; LigaPASS, a band connector for posterior thoracic fixation; and PASS ANT, a polyaxial low profile thoraco-lumbar system for anterior approach. The company also provides a range of implants for the cervical spine, including C-JAWS, an anterior cervical spinal fixation system; IMPIX C, a sterile PEEK optima cervical inter body device; Impix C+, a sterile PEEK optima cervical inter body device that is prefilled with bone substitute; and IMPIX-MANTA, a sterile PEEK optima cervical inter body device, which is preassembled on holder and delivers with disposable instrumentation kit. Its implants for cervical spine also include IMPIX-MANTA +, a sterile PEEK optima cervical inter body device, which is prefilled with bone substitutes, as well as preassembled on disposable holder/impactor and delivered with disposable instrumentation kit; and GRANVIA C, a MRI compatible ceramic cervical disc. In addition, the company offers implants and bone substitutes for the thoracic and lumbar spine, such as IMPIX-L, a sterile PEEK optima lumbar inter body device for posterior approach; IMPIX-TLIF, a sterile PEEK optima lumbar inter body device for transformational approach; IMPIX ALIF, a sterile PEEK optima lumbar inter body device for anterior approach; STABOLT, a lumbosacral anterior plating system; OSMOSYS, a macro porous bone substitute; IMPIX-DLIF and IMPIX-DLIF SLIM sterile PEEK optima lumbar interbody devices for direct or oblique lateral approach; and IMPIX-S, an oblique TLIF interbody device. Its implants are designed to treat scoliosis, degenerative deformation, trauma, and tumors; and are used in various traditional and advanced surgical techniques, such as minimally-invasive surgery. The company was founded in 1990 and is based in Rillieux-la-Pape, France.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.